Prognostic Value of p16 Promoter Hypermethylation in Colorectal Cancer: A Meta-Analysis

REFERENCES

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2(2):103–112.
   PubMed Web of Science ®Google Scholar
• Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1(7): 686–692.
   PubMed Web of Science ®Google Scholar
• Schuebel KE, Chen W, Cope L, Glockner SC, Suzuki H, Yi JM, Chan TA, Van Neste L, Van Criekinge W, van den Bosch S, van Engeland M, Ting AH, Jair K, Yu W, Toyota M, Imai K, Ahuja N, Herman JG, Baylin SB. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 2007;3(9):1709–1723.
   PubMed Web of Science ®Google Scholar
• Tsai HC, Baylin SB. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res 2011;21(3):502–517.
   PubMed Web of Science ®Google Scholar
• Kim BN, Yamamoto H, Ikeda K, Damdinsuren B, Sugita Y, Ngan CY, Fujie Y, Ogawa M, Hata T, Ikeda M, Ohue M, Sekimoto M, Monden T, Matsuura N, Monden M. Methylation and expression of p16INK4 tumor suppressor gene in primary colorectal cancer tissues. Int J Oncol 2005;26(5):1217–1226.
   PubMed Web of Science ®Google Scholar
• Mitomi H, Fukui N, Tanaka N, Kanazawa H, Saito T, Matsuoka T, Yao T. Aberrant p16((INK4a)) methylation is a frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity. J Cancer Res Clini Oncol 2010;136(2):323–331.
   PubMed Web of Science ®Google Scholar
• Liang JT, Chang KJ, Chen JC, Lee CC, Cheng YM, Hsu HC, Wu MS, Wang SM, Lin JT, Cheng AL. Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: association with DNA replication error and shorter survival. Oncology 1999;57(2):149–156.
   PubMed Web of Science ®Google Scholar
• Maeda K, Kawakami K, Ishida Y, Ishiguro K, Omura K, Watanabe G. Hypermethylation of the CDKN2A gene in colorectal cancer is associated with shorter survival. Oncol Rep 2003;10(4): 935–938.
   PubMed Web of Science ®Google Scholar
• Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, Chapusot C, Piard F. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008;68(20):8541–8546.
   PubMed Web of Science ®Google Scholar
• Kim JC, Choi JS, Roh SA, Cho DH, Kim TW, Kim YS. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas. Ann Surg Oncol 2010;17(7):1767–1776.
   PubMed Web of Science ®Google Scholar
• Wettergren Y, Odin E, Carlsson G, Gustavsson B. MTHFR, MTR, and MTRR polymorphisms in relation to p16INK4A hypermethylation in mucosa of patients with colorectal cancer. Mol Med (Cambridge, Mass) 2010;16(9–10):425–432.
   PubMed Web of Science ®Google Scholar
• Bihl MP, Foerster A, Lugli A, Zlobec I. Characterization of CDKN2A(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing. J Transl Med 2012;10:173.
   PubMed Web of Science ®Google Scholar
• Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR, Herman JG, Capella G, Peinado MA. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001;19(2):299–304.
   PubMed Web of Science ®Google Scholar
• Ward RL, Cheong K, Ku SL, Meagher A, O'Connor T, Hawkins NJ. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol 2003;21(20):3729–3736.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Quevedo R, Garcia-Aranda C, Moran A, De Juan C, Sanchez-Pernaute A, Torres A, Diaz-Rubio E, Balibrea JL, Benito M, Iniesta P. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implications. Int J Oncol 2004;24(2):349–355.
   PubMed Web of Science ®Google Scholar
• Sanz-Casla MT, Maestro ML, Vidaurreta M, Maestro C, Arroyo M, Cerdan J. p16 gene methylation in colorectal tumors: correlation with clinicopathological features and prognostic value. Dig Dis 2005;23(2):151–155.
   PubMed Web of Science ®Google Scholar
• Ishiguro A, Takahata T, Saito M, Yoshiya G, Tamura Y, Sasaki M, Munakata A. Influence of methylated p15 and p16 genes on clinicopathological features in colorectal cancer. J Gastroenterol Hepatol 2006;21(8):1334–1339.
   PubMed Web of Science ®Google Scholar
• Shen L, Catalano PJ, Benson AB 3rd, O'Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 2007;13(20):6093–6098.
   PubMed Web of Science ®Google Scholar
• Miladi-Abdennadher I, Abdelmaksoud-Damak R, Ayadi L, Khabir A, Frikha F, Kallel L, Frikha M, Sellami-Boudawara T, Gargouri A, Mokdad-Gargouri R. Aberrant methylation of hMLH1 and p16INK4a in Tunisian patients with sporadic colorectal adenocarcinoma. Biosci Rep 2011;31(4):257–264.
   PubMed Web of Science ®Google Scholar
• Shima K, Nosho K, Baba Y, Cantor M, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: cohort study and literature review. Int J Cancer 2011;128(5):1080–1094.
   PubMed Web of Science ®Google Scholar
• Iida S, Kato S, Ishiguro M, Matsuyama T, Ishikawa T, Kobayashi H, Higuchi T, Uetake H, Enomoto M, Sugihara K. PIK3CA mutation and methylation influences the outcome of colorectal cancer. Oncol Lett 2012;3(3):565–570.
   PubMed Web of Science ®Google Scholar
• Han SW, Lee HJ, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. Int J Cancer 2013;132(9):2209–2216.
   PubMed Web of Science ®Google Scholar
• Veganzones-de-Castro S, Rafael-Fernandez S, Vidaurreta-Lazaro M, de-la-Orden V, Mediero-Valeros B, Fernandez C, Maestro-de las Casas ML. p16 gene methylation in colorectal cancer patients with long-term follow-up. Rev Esp Enferm Dig 2012;104(3):111–117.
   PubMed Web of Science ®Google Scholar
• Wells GA SB, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in metaanalyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
   Google Scholar
• Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhong W. Applied Methodology for Evidence-Based Medicine. Changsha, China: Central South University Press, 2012, 163.
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177–188.
   PubMedGoogle Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol 2008;61(8):763–769.
   PubMed Web of Science ®Google Scholar
• Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol 2009;9:86.
   PubMed Web of Science ®Google Scholar
• Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trial 1997;18(6):580–593; discussion 661–586.
   PubMedGoogle Scholar
• Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol 2008;37(5): 1148–1157.
   PubMed Web of Science ®Google Scholar
• Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 1999(47):15–17.
   Google Scholar
• Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56(2):455–463.
   PubMed Web of Science ®Google Scholar
• Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 2010;29(1):181–206.
   PubMed Web of Science ®Google Scholar
• Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn 2008;10(1):13–27.
   PubMed Web of Science ®Google Scholar
• Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23(3):609–618.
   PubMed Web of Science ®Google Scholar
• Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003;9(8):2898–2903.
   PubMed Web of Science ®Google Scholar